| Recruiting | 3b | 500000 | RoW | Booster vaccine | Wits Health Consortium (Pty) Ltd, National Department of Health of South Africa, National Institute of Communicable Diseases - NICD, KwaZulu-Natal Research Innovation and Sequencing Platform - KRISP, Fred Hutchinson Cancer Center, Hutchinson Center Research Institute of South Africa (HCRISA), Janssen Vaccines & Prevention B.V., Bio Analytical Research Corporation, Dis-Chem Pharmacy, BioVac, Biocair, Right to Care, Clinical Laboratory Services, Institute of Infectious Disease and Molecular Medicine | SARS CoV 2 Infection | 01/22 | 06/23 | | |
| Recruiting | 2 | 2500 | RoW | GSK3036656, BTZ-043, Bedaquiline (B), Delamanid (D), Pretomanid (Pa), Moxifloxacin (M), Linezolid (L), Pyrazinamide (Z), Rifampicin (R), Isoniazid (H), Ethambutol (E) | University College, London, Radboud University Medical Center, London School of Hygiene and Tropical Medicine, University of Oxford, Research Center Borstel, Lygature, TASK Applied Science, Vita-Salute San Raffaele University, Helmholtz Zentrum Munchen, KNCV Tuberculosis Foundation, Critical Path Institute, European Lung Foundation, Instituto de Saude Publica da Universidade do Porto, University of Liverpool, Institut de Recherche Pour le Developpment, University of Hamburg-Eppendorf, University of California, San Francisco, TB Alliance, Find, University of Milano, University of St Andrews, Uppsala University, European Respiratory Society, Tuberculosis Network European Trialsgroup, Janssen, LP, Otsuka Pharmaceutical Development & Commercialization, Inc., German Center for Infection Research, LMU University Hospital Munich, University of Cambridge, GlaxoSmithKline | Pulmonary Tuberculosis | 02/27 | 08/27 | | |